प्राथमिक स्रोत रिकॉर्ड
महत्वपूर्णPDUFA तारीख़ तय
गिलियड: FDA ने BIC/LEN की NDA के लिए PDUFA तिथि 27 अगस्त 2026 तय की
FDA accepted the NDA for BIC/LEN under priority review. The agency assigned a PDUFA target action date of August 27, 2026, establishing the regulatory timeline for this single-tablet regimen in virologically suppressed HIV patients.
मुख्य तथ्य
- फाइल किया गया
- 7 मई 2026, 08:03 pm
- घटना
- PDUFA तारीख़ तय
- दिशा
- तटस्थ
- कंपनी
GILDगिलियड- संपत्ति
- bictegravir and lenacapavir
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- कैलेंडर
- FDA फ़ैसला (PDUFA) · 27 अग॰ 2026 · परिणाम दर्ज नहीं
स्रोत का अंश
EX-99.1 2 exhibit991earningspressrel.htm EXHIBIT 99.1 Document GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Foster City, CA, May 7, 2026 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Building on the strongest pipeline in Gilead’s history, we are adding potentially
इस संपत्ति पर और
महत्वपूर्ण
29 अप्रैल 2026
12:30 pm
GILDगिलियड